WO2005071075A1 - 上皮細胞増殖因子受容体(egfr)由来ペプチド - Google Patents
上皮細胞増殖因子受容体(egfr)由来ペプチド Download PDFInfo
- Publication number
- WO2005071075A1 WO2005071075A1 PCT/JP2005/000786 JP2005000786W WO2005071075A1 WO 2005071075 A1 WO2005071075 A1 WO 2005071075A1 JP 2005000786 W JP2005000786 W JP 2005000786W WO 2005071075 A1 WO2005071075 A1 WO 2005071075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egfr
- peptide
- cells
- hla
- cancer
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 188
- 108060006698 EGF receptor Proteins 0.000 title claims description 151
- 102000001301 EGF receptor Human genes 0.000 title claims description 141
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 58
- 229920001184 polypeptide Polymers 0.000 claims abstract description 26
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 16
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 15
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 15
- 230000001939 inductive effect Effects 0.000 claims abstract description 13
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 36
- 238000009566 cancer vaccine Methods 0.000 claims description 11
- 229940022399 cancer vaccine Drugs 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 7
- 231100000433 cytotoxic Toxicity 0.000 claims description 4
- 230000001472 cytotoxic effect Effects 0.000 claims description 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 abstract description 39
- 201000011510 cancer Diseases 0.000 abstract description 24
- 230000028996 humoral immune response Effects 0.000 abstract description 11
- 230000024932 T cell mediated immunity Effects 0.000 abstract description 9
- 238000009169 immunotherapy Methods 0.000 abstract description 6
- 239000000203 mixture Substances 0.000 abstract description 2
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 1
- 229940027941 immunoglobulin g Drugs 0.000 description 28
- 210000002966 serum Anatomy 0.000 description 21
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 18
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 18
- 210000004881 tumor cell Anatomy 0.000 description 16
- 108010013476 HLA-A24 Antigen Proteins 0.000 description 15
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 15
- 230000002788 anti-peptide Effects 0.000 description 14
- 150000001413 amino acids Chemical group 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 239000013642 negative control Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000000427 antigen Substances 0.000 description 9
- 230000000875 corresponding effect Effects 0.000 description 9
- 230000006698 induction Effects 0.000 description 9
- 102100037850 Interferon gamma Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 238000003556 assay Methods 0.000 description 7
- 238000011282 treatment Methods 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 6
- 238000000692 Student's t-test Methods 0.000 description 6
- 229960002584 gefitinib Drugs 0.000 description 6
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 5
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 238000002255 vaccination Methods 0.000 description 5
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 4
- 102400001368 Epidermal growth factor Human genes 0.000 description 3
- 101800003838 Epidermal growth factor Proteins 0.000 description 3
- 206010061535 Ovarian neoplasm Diseases 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 208000037887 cell injury Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 229940121647 egfr inhibitor Drugs 0.000 description 3
- 229940116977 epidermal growth factor Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 108091033319 polynucleotide Proteins 0.000 description 3
- 102000040430 polynucleotide Human genes 0.000 description 3
- 239000002157 polynucleotide Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 101710100968 Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 210000002861 immature t-cell Anatomy 0.000 description 2
- 230000008076 immune mechanism Effects 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229940023041 peptide vaccine Drugs 0.000 description 2
- 238000009520 phase I clinical trial Methods 0.000 description 2
- 238000011471 prostatectomy Methods 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000002626 targeted therapy Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000012657 Atopic disease Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 108010080347 HLA-A*26 antigen Proteins 0.000 description 1
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
- 108700038332 Histone deacetylase 11 Proteins 0.000 description 1
- 102100039385 Histone deacetylase 11 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010062904 Hormone-refractory prostate cancer Diseases 0.000 description 1
- 102000008100 Human Serum Albumin Human genes 0.000 description 1
- 108091006905 Human Serum Albumin Proteins 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- FTFRZXFNZVCRSK-UHFFFAOYSA-N N4-(3-chloro-4-fluorophenyl)-N6-(1-methyl-4-piperidinyl)pyrimido[5,4-d]pyrimidine-4,6-diamine Chemical compound C1CN(C)CCC1NC1=NC=C(N=CN=C2NC=3C=C(Cl)C(F)=CC=3)C2=N1 FTFRZXFNZVCRSK-UHFFFAOYSA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 101710107444 Polyamine deacetylase HDAC10 Proteins 0.000 description 1
- 102100039388 Polyamine deacetylase HDAC10 Human genes 0.000 description 1
- 102400000745 Potential peptide Human genes 0.000 description 1
- 101800001357 Potential peptide Proteins 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 1
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 210000000628 antibody-producing cell Anatomy 0.000 description 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 190000008236 carboplatin Chemical compound 0.000 description 1
- 229960004562 carboplatin Drugs 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000012875 competitive assay Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 102000054766 genetic haplotypes Human genes 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000006654 negative regulation of apoptotic process Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 239000003909 protein kinase inhibitor Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000022120 response to tumor cell Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- EGFR Epidermal growth factor receptor
- the present invention relates to an EGFR-derived peptide that can be used for EGFR-based cancer immunotherapy. Specifically, the present invention relates to a polypeptide containing an EGFR-derived peptide capable of inducing both cellular and humoral immune responses, a cancer vaccine containing the peptide, and the like.
- EGFR Epidermal growth factor receptor
- EGFR is part of a family of receptors that consists of EGFR and four very similar proteins, including HER2, HER3 and HER4. This family of proteins also has extracellular ligand binding, transmembrane, and intracellular tyrosine kinase domain forces (Non-Patent Document 20). Binding of ligands such as epidermal growth factor (EGF) activates tyrosine kinases in the intracellular domain, triggering receptor autophosphorylation and activating signaling cascades involved in cell growth and survival (Non-Patent Document 20).
- EGF epidermal growth factor
- EGFR activation involves processes necessary for tumor growth and progression, including cell proliferation, inhibition of apoptosis, angiogenesis and metastasis (Non-Patent Document 19).
- EGFR is one of the most suitable target molecules for cancer treatment because it is correlated with tumor exacerbation, which is relatively high in about one-third of all epithelial cancers (Non-patent literature). 21, 22).
- Non-Patent Documents 4 and 5 a novel EGFR tyrosine kinase inhibitor, is known to be effective for treating patients with advanced non-small cell lung cancer (NSCLC) (Non-Patent Documents 4 and 5).
- NSCLC non-small cell lung cancer
- CTLs cytotoxic T cells
- HLA major histocompatibility complex
- Non-patent Documents 6-9 It has been reported in the past 10 years that an epitope peptide of HER2 / neu, which is one of the EGFR receptor families, can induce HLA class I-restricted CTL.
- the present inventors reported that some CTL-recognizing peptides derived from non-mutant growth-related proteins were capable of inducing both cellular and humoral immune responses in vivo (non- Patent Document 10-12).
- anti-peptide antibody levels in post-vaccine serum have been found to be in good agreement with the overall survival of advanced lung cancer patients receiving peptide vaccination (Non-Patent Document 12).
- Non-Patent Document 12 There is a body of evidence suggesting that peptides capable of inducing both cellular and humoral immune responses by calorie are more immunogenic (Non-patent Documents 13-15), and stronger therapeutic activity can be expected.
- Cytotoxic T cell (CTL) recognition epitope is a therapeutically useful compound different from existing compounds as a peptide vaccine for cancer patients with tumors that overexpress it in EGFR targeted therapy. Can be. However, there is currently no information on the EGFR CTL recognition epitope.
- Non-patent document 1 Yamamoto, T., Ikawa, S., Akiyama, T., Semba, K., Nomura, N.,
- Non-Patent Document 2 Coussens, L., Yang-Feng, TL, Liao, Y.-C., Chen, E., Gray, A., McGrath, J., Seeburg, PH, Libermann, TA, Schlessinger, J ., Francke, U., Levinson, A., and Ullrich, A. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location neu oncogene.Science, 230: 1132-1139, 1985.
- Patent Document 3 Salomon, DS, Brandt, R., Ciardiello, F., and Normanno, N. Epidermal growth factor-related peptides and their receptors in human malignancies.Crit. Rev.Oncol.HematoL, 19: 183-232, 1995.
- Non-Patent Document 4 Miller, V. A "Johnson, DH, Krug, LM, Pizzo, B., Tyson, L” Perez, W., Krozely, P., Sandler, A., Carbone, D., Heelan, RT, Kris, MG., Smith, R., and Ochs, J. Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.J. Clin. Oncol, 21: 2094-2100, 2003.
- Non-language reference 5 Fukuoka, M., Yano, S., uiaccone, G., Tamura, ⁇ , Nakagawa, ⁇ , Douillard, J. ⁇ , Nishiwaki, ⁇ , Vansteenkiste, J., Kudoh, S., Rischin, D., Eek, R., Horai, ⁇ ⁇ , Noda, ⁇ ⁇ , Takata, I., Smit, mit ⁇ , Averbuch, S., Macleod, A., Feyereislova, A., Dong, RP, and Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer.J. Clin. Oncol, 21: 2237-2246, 2003.
- Non-special reference literature b Peoples, G. ⁇ , Goedegebuure, PS, Smith, R., Linehan, DC, Yoshino, I., and Eberlein, T. j. Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2 / neu—derived peptide. Proc. Natl. Acad. Sci. USA, 92: 432-436, 1995.
- Non-Patent Document 7 Fisk, ⁇ ⁇ , Blevins, ⁇ ⁇ L., Wharton, J.T ”and loannides, C.G.
- Non-special reference literature 8 Kawashima, 1, Tsai, V., Southwood, S., Takesako, ⁇ , Sette, A., and Celis, E. Identification of HLA— A3— restricted cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2 / neu by primary in vitro immuneization with peptide-pulsed dendritic cells.Cancer, Res., 59: 431-435, 1999.
- Non-Patent Document 9 Okugawa, T., Ikuta, ⁇ ., Takahashi, ⁇ ., Obata, ⁇ ., Tanida, ⁇ .,
- HLA human HER2— derived peptide homologous to the mouse Kd— restricted tumor rejection antigen can induce HLA— A24— restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.
- HLA restricted cytotoxic T lymphocytes in ovarian cancer patients and healthy individuals.
- Special Reference No. 10 Noguchi, M., Kobayashi, ⁇ , Suetsugu, ⁇ , Tomiyasu, ⁇ , Suekane, S., Yamada, A. Jtoh, K. and Noda, S. Induction Of Cellular And Humoral Immune Responses To Tumor Cells And Peptides In HLA-A24 Positive
- Hormone RefractoryProstate Cancer Patients By Peptide Vaccination. Prostate, in press, 2003.
- Non-patent literature ll Sato, Y., Shomura, H., Maeda, Y., Mine, T., Une, Y., Akasaka, Y., Kondo, M., Takahasni, S., Shinohara, ⁇ ⁇ , Katagin, ⁇ ⁇ , Sato, S., Okada, S., Matsui, ⁇ ⁇ , Yamada, A., Yamana, ⁇ ⁇ , Itoh, ⁇ ⁇ , and Todo, S. Immunological evaluation of peptide vaccination for patients with gastric cancer based on pre-existing cellular response to peptide.Cancer 3 ⁇ 4ci., in press, 2003.
- Non-Patent Document 12 Mine, ⁇ ⁇ , Gouhara, R., Hida, ⁇ ⁇ , Imai, ⁇ ⁇ , Azuma, ⁇ ⁇ , Rikimaru, ⁇ ⁇ , Katagin, ⁇ ⁇ , Nishikori, M., Sukehiro, A., Nakagawa, M., Yamada, A., Aizawa, ⁇ , Shirouzu, ⁇ , Itoh, ⁇ , and Yamana, H. Immunological evaluation of CTL
- Non-special reference literature 13 Parkar, M. ⁇ ⁇ , Kuru, L., uiouzeli, M., and Olsen, I. Expression of growth-factor receptors in normal and regenerating human periodontal cells. Arch. Oral. Biol., 46 : 275-284, 2001.
- Non-Patent Document 14 Disis, ML, Pupa, SM, Gralow, J.R "Dittadi, R” Menard, S "and Cheever, MA High-titer HER-2 / neu protein-specific antibody can be detected in patients with early -stage breast cancer. J. Clin. Oncol., 11: 3363-3
- Non-Patent Reference 15 Jager, ⁇ ⁇ , Gnjatic, S., Nagata, ⁇ ⁇ , Stockert, ⁇ ⁇ , Jager, D., Karbach J , Neumann, A., Rieckenberg, J., Chen, Y.
- Non-Patent Document 16 Ohkouchi, S., Yamada, A “Imai, N” Mine, T “Harada, K” Shichijo, S., Maeda, ⁇ ⁇ , Saijo, ⁇ ⁇ , Nukiwa, ⁇ ⁇ , and Itoh, K .
- Non-mutated tumor-rejection antigen peptides elicit type—I allergy in the majority of healthy individuals.Tissue Antigens, 59: 259-272, 2002.
- Non-Patent Document 17 Kawamoto, ⁇ ⁇ , Yamada, A., Ohkouchi, S., Maeda, T., Tanaka, S., Hashimoto, ⁇ ⁇ , Saijo, ⁇ ⁇ , ⁇ aijo, S., Nukiwa, ⁇ ⁇ , Shichijo, S., Aizawa, ⁇ ⁇ , and Itoh, K. IgG reactive to CTL—directed epitopes of self-antigens is enter lacking or unbalanced in atopic dermatitis patients. Tissue Antigen, 61: 352—361, 2003.
- Non-Patent References 19 Dancey, J. & Sausville, EA.Issues and progress with protein kinase inhibitors for the treatment of cancer.Nature Rev. Drug Discov. 2, 325-334 (2003).
- Non-Patent Document 20 Yarden, Y. & Sliwkowski, M.X.Untangling the ErbB signaling network.Nature Rev. Mol. Cell Biol. 2, 127-137 (2001).
- Non-special reference 21 Baselga, J. Why the epidermal growth factor receptor? The rationale for cancer therapy. The Oncologist 7 (S4), 2-8 (2002).
- Non-Patent Document 23 Herbst RS, Maddox AM, Rothenberg ML, Small EJ, Rubin EH, Baselga J, Rojo F, Hong WK, Swaisland H, Averbuch SD, Ochs J, LoRusso PM (2002) Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD 1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumor: results of a phase I trial.J Clin Oncol 20: 3815-3825.
- Non-Patent Document 24 Dittrich Ch, Greim G, Borner M, Weigang-Kohler K, Huisman H, Amelsberg A, Ehret A, Wanders J, Hanauske A, Fumoleau P (2002) Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration.Eur J Cancer 38: 1072-1080.
- EGFR epidermal growth factor receptor
- Non-Patent Document 25 Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the Diology and treatment of cancer.J Clin Oncol 21:
- An object of the present invention is to provide a peptide that is a candidate for a cancer vaccine from the viewpoint of developing EGFR-based cancer therapy.
- EGFR-derived peptides that induce a humoral immune response
- EGFR-derived peptides having specific antibodies in the serum of NSCLC patients and healthy donors (HD) were examined.
- the present invention was completed because these peptides were able to induce cytotoxic T cells that specifically damage tumor cells by EGFR.
- the present invention provides:
- nucleic acid molecule encoding the peptide according to (1) or (2) or a polypeptide comprising the peptide
- an EGFR-reactive cytotoxic T cell that recognizes the peptide of (1) or (2) or the complex of the polypeptide of (3) and HLA;
- FIG. 1 Representative histogram of EGFR expression in tumor cells by flow cytometry assay.
- the dotted line indicates only the secondary antibody (FITC binding control antibody), and the black line indicates the anti-EGFR monoclonal antibody and the secondary antibody.
- FIG. 2 is a graph showing the results of detecting anti-peptide IgG in a serum sample.
- FIG. 3A is a graph showing the results of examining the peptide specificity of anti-peptide IgG in a serum sample.
- FIG. 3B is a graph showing the results of examining the cross-reactivity of anti-peptide IgG to full-length EGFR protein.
- FIG. 4 is a graph showing CTL induction by an EGFR-derived peptide. * P less 0.05 (Student t test).
- FIG. 5 is a graph showing the cytotoxicity of peptide-stimulated PBMC on cancer cell lines. * P ⁇ 0.05 (two-tailed Student's t test).
- FIG. 6 is a graph showing HLA restriction and peptide specificity of cytotoxicity due to inhibition and competition.
- FIG. 7 is a graph showing detection results of anti-peptide IgG in a serum sample.
- FIG. 8 is a graph showing the results of examining the peptide specificity of anti-peptide IgG.
- FIG. 9 is a graph showing CTL induction by an EGFR-derived peptide.
- PBMC of HLA-A2 + cancer patients were stimulated with a peptide and pulsed with the corresponding peptide.
- T2 cells HLA-A2, TB hybridoma ) was measured for IFN- ⁇ production. * P ⁇ 0.05 (Student's t-test).
- FIG. 10 is a graph showing the cytotoxicity of peptide-stimulated PBMC on cancer cell lines.
- SKOV3-A2 HLA-A2 +, EGFR
- SKOV3 HLA-A2-, EGFR +
- FIG. 11 is a graph showing HLA restriction of cytotoxicity and peptide specificity due to inhibition and competition. Peptide-pulsed T2 cells were used for competition.
- the EGFR-derived peptide of the present invention is a highly immunogenic peptide that induces both cellular and humoral immune responses.
- the present inventors have reported that IgG that reacts with the CTL epitope peptide is often detected in pre-vaccinated cancer patients and serum of HD (Non-Patent Documents 10-12, 16). , 17).
- some CTL-recognizing peptides can induce both cellular and humoral immunity in vivo in phase I clinical trials, and levels of anti-peptide IgG in sera after vaccination have progressed with peptide vaccination. This is in good agreement with the overall survival rate of cancer patients (Non-Patent Documents 11 and 12).
- Non-Patent Documents 23, 24, 25 the peptide according to the present invention can be used as a cancer vaccine useful in treating EGFR-targeted cancer.
- the peptide of the present invention is an HLA-A24 or HLA-A2-restricted peptide.
- Specific examples of peptides that induce both cellular and humoral immune responses include EGFR (SEQ ID NO: 1), EGFR (SEQ ID NO: 2), EGFR (SEQ ID NO: 3), and EGFR
- EGFR-derived peptides that induce specific cytotoxic T cells and have a specific antibody-producing ability can be easily determined and selected by a method according to the Examples of the present specification. You can choose. In terms of being able to induce an immune response, EGFR and EGFR are also
- 43-51 943-952 is a potential peptide.
- the present invention also includes a mutant peptide of the peptide having the amino acid sequence of any one of SEQ ID NOs: 1 to 5, which has the same CTL inducing ability and antibody producing ability. . Mutations can be introduced by deleting, substituting, adding, or inserting one or several amino acids to the EGFR-derived peptide of the present invention, and the means are well known in the art. Mutant peptides can be selected using the strength of recognition by CTL as an index. The number of amino acid residues of the mutant peptide is at least about 8 or more, preferably about 9 or more, and more preferably as long as it is a number that is presented on the antigen-presenting cell surface and has properties as a CTL recognition epitope. Is nine or ten.
- the present invention further includes a polypeptide comprising the EGFR-derived peptide of the present invention or a mutant peptide thereof, which has specific CTL inducing ability and antibody-producing ability.
- Polypeptides typically have a length of 8-50 amino acid residues, preferably 8-30, more preferably 9-10 or 8-10.
- the EGFR-derived peptide included is EGFR (SEQ ID NO: 1),
- EGFR (SEQ ID NO: 2), EGFR (SEQ ID NO: 3), EGFR (SEQ ID NO: 4) or
- EGFR SEQ ID NO: 5
- the peptides and polypeptides of the present invention can also be modified by modifying constituent amino acids or carboxyl groups to such an extent that the function is not significantly impaired.
- the peptides and polypeptides of the present invention can be produced by a generally known method in peptidomiridism.
- the nucleic acid molecule of the present invention includes single-stranded (including complementary) and double-stranded polynucleotides encoding the amino acid sequence of the EGFR-derived peptide of the present invention or a mutant peptide thereof and a polypeptide containing the peptide. .
- the nucleic acid molecule of the present invention may be DNA or RNA. Peptides having an amino acid sequence encoded by these nucleic acid molecules can be recognized by CTL, activate the CTL, and function as a tumor antigen.
- the nucleic acid molecule of the present invention may be a polynucleotide having at least 24 or more basic strengths corresponding to the region encoding the peptide of the present invention and a complementary strand thereof.
- a polynucleotide can be selected, for example, by confirming the expressed peptide using a known protein expression system.
- the antibody of the present invention also specifies a peptide or polypeptide that has at least five consecutive amino acid residues in the amino acid sequence of one peptide or polypeptide, which is also selected for the neutrality of the EGFR-derived peptide or polypeptide of the present invention. It is something to recognize.
- the antibodies can be made using these epitope peptides, which are composed of at least 5, preferably at least 8-10 amino acids.
- the invention also includes a peptide comprising at least five amino acid residues and a nucleic acid molecule encoding the same.
- the amino acid sequence of the epitope may not be completely identical to the amino acid sequence described in any of SEQ ID NOs: 1 to 5, but it is necessary that at least a peptide consisting of the amino acid sequence is recognized by CTL. .
- the antibody of the present invention can be used to immunize mice, rats, rabbits, goats, and the like, in the presence or absence of an adjuvant, alone or in the form of an epitope peptide derived from EGFR or a carrier bound thereto. , Can induce production.
- the obtained polyclonal antibody can be recovered from serum by a known method.
- monoclonal antibodies can be produced by fusing antibody-producing cells recovered from animals that have induced an immune response as described above with permanently proliferating cells. This method is well known in the art.
- polyclonal and monoclonal antibodies can be used as purification antibodies, reagents, labeling markers, and the like.
- the anti-EGFR peptide IgG which has not been shown in the present specification, has not shown direct inhibition of tumor cell growth in vitro when tested so far, and has antibody-dependent cell-mediated cytotoxicity against tumor cells. Also could not be induced. As such, the anti-EGFR peptide IgG may not act directly on tumor cells.
- the pharmaceutical composition of the present invention comprises the EGFR-derived peptide or polypeptide of the present invention, a nucleic acid molecule encoding the same, a vector prepared based on the nucleotide sequence information of the nucleic acid molecule, or the antibody of the present invention, alone or in combination. It can be prepared by using in combination. Specifically, the EGFR-derived peptide of the present invention or a mutant thereof and a polypeptide containing the peptide can be used as a cancer vaccine.
- the pharmaceutical composition of the present invention is useful as a cancer vaccine in EGFR-based immunotherapy. It can be used to treat tumors, spleen cancer, etc.
- EGFR-targeted cancer treatment refers to, for example, an antagonist of a ligand (in this case, EGF) or a signal transmitter (eg, since EGFR is a receptor for cell growth factor EGF) It is conceptually broad, including treatment with inhibitors of the body (including signal transduction).
- EGF ligand
- signal transmitter eg, since EGFR is a receptor for cell growth factor EGF
- EGFR-based immunotherapy refers to a narrow concept when EGFR is an antibody or is a target molecule of T cells.
- the pharmaceutical composition of the present invention even one kind of peptide is effective as a cancer vaccine, but it is preferable to use a combination of plural kinds of peptides. This is because the CTLs of cancer patients are a population of cells that recognize multiple different types of tumor antigens, so it is expected that using multiple types of tumor antigens in combination as a cancer vaccine will be more effective It is Kara.
- a plurality of the peptides according to the present invention may be used in combination.
- the peptide or polypeptide for the cancer vaccine of the present invention may be used alone or in combination with or bound to a pharmaceutically acceptable carrier in the presence or absence of a suitable adjuvant.
- a pharmaceutically acceptable carrier in the presence or absence of a suitable adjuvant.
- the carrier is not limited as long as it does not cause harmful effects on the human body.
- cellulose, polymerized amino acids, albumin and the like can be used.
- As the dosage form a dosage form known for peptide preparations can be selected.
- the dose is 0.01-100 mg / day / adult human, preferably 0.1-10 mg / day / adult human, as the active substance which changes depending on the recognition by CTL. It is administered once every few days or months.
- the pharmaceutical composition of the present invention can also contain a nucleic acid sequence encoding the peptide of the present invention incorporated in an appropriate vector, and is introduced in vivo or ex vivo.
- the vector include a retrovirus, an adenovirus, a vaccinia virus and the like, and a retrovirus system is preferable.
- the dose is 0.1 ⁇ g-100 mg / day / adult human, preferably 1 ⁇ g-50 mg / day / adult human, as the power DNA content that varies depending on the recognition by CTL. It is administered once every few days or months.
- EGFR-reactive CTL are induced, for example, from peripheral blood mononuclear cells (PBMC) of NSCLC patients using the peptide of the present invention.
- PBMC peripheral blood mononuclear cells
- PBMC of an NSCLC patient are incubated with antigen-presenting cells (APC) pulsed with the peptide of the present invention to induce CTL, and evaluated using IFN- ⁇ production as an index. Furthermore, the induced CTL activity can be confirmed by using 51 Cr-releasing assay using tumor cytotoxicity as an index.
- APC antigen-presenting cells
- This method can be used for adoptive immunotherapy, in which antigen-specific CTLs induced in vitro are returned to the patient and tumor cells are damaged.
- Non-Patent Document 11 serum samples are serially diluted with 0.05% Tween 20-Block Ace (Snow Brand Milk Products, Hokkaido, Japan) and peptide (20 g / well) immobilized on Nunc Covalink plates (Fisher Scientific, Pittsburgh, PA) The diluted serum was cultivated at 100 1 / ⁇ . ⁇ ⁇ ⁇ ⁇ Peptidic antibodies were detected by heron anti-herb HgG (y chain specific) (DAKO, Glostrp, Denmark).
- ELISA enzyme-linked immunosorbent assay
- the sera obtained from HD10 (HIV negative) sera were used to measure the reactivity to HIV peptide by the assay. Since the average SD of the absorbance (A) was 0.020 ⁇ 0.02, the average + SD value (0.04) was defined as the cutoff value.
- FIG. 2 shows representative results of three NSCLC patients (Pt. 2, 3, and 10) and three HDs (HD. 2, 4, and 10).
- the A value for the HIV control, a negative control, is subtracted from the data.
- Table 1 summarizes the results for 11 peptides for which some sera gave a positive response.
- IgG reacting with EGFR, EGFR and EGFR peptide are 8, 7,
- EGFR EGFR and significant levels of IgG responsive to EGFR were shown.
- EGFR EGFR
- EGFR EGFR
- EGFR EGFR
- EGFR EGFR
- EGFR EGFR
- EGFR EGFR
- the peptide specificity of the tide IgG was confirmed by an absorption test.
- FIG. 3A Representative results for sera of Pt. 3, 8, 10, and 13 are shown in FIG. 3A.
- the activity of these sera in response to each of the three peptides was absorbed by the corresponding peptide, but not by the HIV peptide used as a negative control (FIG. 3A).
- IFN-y production was examined using NBCLC cancer patients and HD PMBC as an index.
- IFN- ⁇ was measured by ELISA. Data power was also subtracted from background IFN- ⁇ production for HIV peptide (about 50 pg / ml). As a control for their CTL inducing ability, two peptides (EGFR and EGFR) for which no IgG response was detected were similarly tested.
- PBMC peripheral blood mononuclear cells
- EGFR, EGFR and EGFR peptide can induce cytotoxic T cells
- the cytotoxicity of peptide-stimulated PBMC was evaluated by 51 Cr release assay for 6 hours to confirm CTL induction.
- Non-patent Document 13 an immunofluorescence-labeled anti-EGFR monoclonal antibody (mAb) (Santa Cruz Biotechnology, Santa Cruz, CA). A431 tumor cells and phytohematologica (PHA) immature T cells were used as positive and negative controls, respectively.
- Figure 1 shows representative results of the histogram.
- tumor cell lines were used as target cells in the 51 Cr-releasing Atsey: 11-18 (HLA-A24 / 2, human lung adenocarcinoma, EGFR "), QG56 (HLA-A26, Lung squamous cell carcinoma (SCC), EGFR +), Sq-1 (HLA-A24 / ll, lung SCC, EGFR *), LC65A (HLA-A24 / ll, non-small cell lung cancer, EGFR "), SKOV3 (HLA- A3 / 28, ovarian cancer, EGFR "), and SKOV3-A24 (HLA-A-24-transformed SKOV3).
- PHA blast-transformed T cells from PMBC were used as a negative control for target cells for 51 Cr-releasing Atsusei. (Non-Patent Document 12).
- FIG. Values represent mean SD of specific lysis (%).
- Peptide-stimulated PBMCs are used in all 11-18 NSCLC cells (HLA-A24 +, EGFR "), LC65A non-small cell lung cancer cells (HLA-A24 +, EGFR +), and SKOV3-A24 (HLA-A24 +, EGFR”) tumor cells
- HLA-A24—, EGFR + a significant level of cytotoxicity QG56 NSCLC cells tested (HLA-A24—, EGFR +), Sq-1 NSCLC cells
- HLA-A24 +, EGFR * HLA-A24 +, EGFR *
- SKOV3 HLA-A24 ", EGFR + tumor cells.
- These PMBCs also failed to kill PHA immature T cells (HLA-A24 +, EGFR-).
- HIV peptide-stimulated PBMC used as a negative control showed no such HLA-A24-restricted cell injury (Fig. 5, bottom of left column). It has HLA-A24-restricted cytotoxicity in response to tumor cells.
- Inhibition experiments included anti-HLA class I (W6 / 32, IgG2a), anti-HLA class II (H-DR-1, IgG2a), anti-CD8 (Nu-Ts / c, IgG2a), anti-CD4 (Nu-Th / i, IgGl) and anti-CD14 (JML-H14, IgG2a) (negative control) monoclonal antibody (20 ⁇ g / ml).
- a competitive assay to study the peptide specificity of cytotoxicity unlabeled C1R-A2402 cells pulsed with the corresponding peptide or HIV peptide (negative control) were used for non-radioactive and radioactive target cells. At a ratio of 10: 1, the mixture was produced into 51 Cr-releasing Atsushi. Values are expressed as mean SD of specific lysis (%), and two-tailed Student's t test was used for statistical analysis.
- the level of cytotoxicity of these peptide-stimulated PBMCs was not inhibited by any of the other monoclonal antibodies tested in this assay, which were significantly inhibited by anti-class I antibodies (W6 / 32) or anti-CD8 monoclonal antibodies.
- the cytotoxicity was also inhibited by the addition of the corresponding peptide pulse C1R-A2402 cells.
- the cytotoxicity was not inhibited by the addition of HIV peptide pulse cells (Fig. 6).
- EGFR and EGFR were identified as EGFR-derived peptides that induce a humoral immune response and an HLA-A2-restricted cellular immune response in the same manner as in Examples 1 and 2.
- Anti-Bubble threat 2. ) 13 4 2 1 10 " 2 n
- Non-Patent Documents 6-9) 124-132 54-62 479-488 1138-1147 Induces both immune and cellular immune responses, resulting in higher immunogenicity compared to the known HER2 / neu-derived CTL epitope peptide. It is suggested that they have (Non-Patent Documents 6-9).
- NSCLC patients who respond to the tyrosine kinase inhibitor ZD1839 are only a fraction of the forces There are currently no laboratory markers suitable for predicting their clinical response. Since findings suggesting that there is a correlation between the level of the immune response to the EGFR peptide of the present invention and the clinical response to ZD1839 have been obtained, it would be more useful if the response to ZD1839 could be predicted by the EGFR-derived peptide of the present invention. (Non-Patent Documents 4, 5).
- HLA-A24aryl which is suggested to be restricted by the EGFR peptide of the present invention, accounts for 60% of Japanese (95% of these cases have the A2402 genotype), 20% of Caucasians, and Africans. 12% of non-patent literature 18). HLA-A2 aril is found in 40% of Japanese, 50% of Caucasians, and 16% of Africans.
- the EGFR peptides of the present invention may provide new insights into the development of EGFR-based immunotherapy that will help a large number of NSCLC patients worldwide.
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/586,499 US7655751B2 (en) | 2004-01-23 | 2005-01-21 | Epidermal growth factor receptor-derived peptides |
EP05704007A EP1712620A4 (en) | 2004-01-23 | 2005-01-21 | PEPTIDE FROM EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) |
JP2005517285A JP4579836B2 (ja) | 2004-01-23 | 2005-01-21 | 上皮細胞増殖因子受容体(egfr)由来ペプチド |
CA2554195A CA2554195C (en) | 2004-01-23 | 2005-01-21 | Peptide originating in epidermal growth factor receptor (egfr) |
US12/141,839 US20080259336A1 (en) | 2004-01-23 | 2008-06-18 | Image processing system and camera |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004015676 | 2004-01-23 | ||
JP2004-015676 | 2004-01-23 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/486,455 Continuation US7826728B2 (en) | 2004-01-23 | 2006-07-13 | Image processing system and camera |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005071075A1 true WO2005071075A1 (ja) | 2005-08-04 |
Family
ID=34805461
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/000786 WO2005071075A1 (ja) | 2004-01-23 | 2005-01-21 | 上皮細胞増殖因子受容体(egfr)由来ペプチド |
Country Status (5)
Country | Link |
---|---|
US (1) | US7655751B2 (ja) |
EP (1) | EP1712620A4 (ja) |
JP (1) | JP4579836B2 (ja) |
CA (1) | CA2554195C (ja) |
WO (1) | WO2005071075A1 (ja) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2196209A1 (en) * | 2007-09-18 | 2010-06-16 | Green Peptide Co., Ltd. | Ctl inducer composition |
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
WO2012005161A1 (ja) | 2010-07-07 | 2012-01-12 | 株式会社グリーンペプタイド | がんペプチドワクチン |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
JP2017029135A (ja) * | 2008-10-01 | 2017-02-09 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
US10137183B2 (en) | 2013-10-21 | 2018-11-27 | Taiho Pharmaceutical Co., Ltd. | Peptide compositions having 4 linked CTL epitopes and uses thereof |
WO2020004622A1 (ja) | 2018-06-29 | 2020-01-02 | 大鵬薬品工業株式会社 | 抗腫瘍剤及びその評価方法 |
WO2021132550A1 (ja) | 2019-12-26 | 2021-07-01 | 大鵬薬品工業株式会社 | 術後補助療法剤 |
CN113518574A (zh) * | 2019-03-05 | 2021-10-19 | 奥林巴斯株式会社 | 内窥镜装置和图像处理方法 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080253993A1 (en) * | 2005-03-31 | 2008-10-16 | Pharmexa A/S | Immunogenic Egfr Peptides Comprising Foreign T Cell Stimulating Epitope |
AU2008262489B2 (en) | 2007-05-23 | 2013-11-28 | Ventana Medical Systems, Inc. | Polymeric carriers for immunohistochemistry and in situ hybridization |
US8329421B2 (en) * | 2007-07-13 | 2012-12-11 | Ventana Medical Systems, Inc. | Methods of predicting response of a neoplasm to an EGFR inhibitor and detecting interactions between EGFR and an EGFR regulatory protein |
SG10201903119QA (en) | 2011-09-06 | 2019-05-30 | Agency Science Tech & Res | Polypeptide vaccine |
JP6158184B2 (ja) * | 2012-08-10 | 2017-07-05 | 株式会社グリーンペプタイド | 上皮成長因子受容体のt790m点突然変異配列に由来する抗原ペプチド |
JP7381345B2 (ja) * | 2017-05-16 | 2023-11-15 | ザ・ジョンズ・ホプキンス・ユニバーシティ | Manaボディおよび使用方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002525382A (ja) * | 1998-09-25 | 2002-08-13 | ザ チルドレンズ メディカル センター コーポレイション | プロテインキナーゼの活性を選択的に調節するショートペプチド |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003298984A1 (en) | 2002-12-27 | 2004-08-23 | Shenzhen Tsinghua Yuanxing Bio-Pharm Science And Technology Co., Ltd. | Method of preparing a vaccine and anti-tumor vaccines |
-
2005
- 2005-01-21 EP EP05704007A patent/EP1712620A4/en not_active Withdrawn
- 2005-01-21 JP JP2005517285A patent/JP4579836B2/ja active Active
- 2005-01-21 US US10/586,499 patent/US7655751B2/en active Active
- 2005-01-21 WO PCT/JP2005/000786 patent/WO2005071075A1/ja active Application Filing
- 2005-01-21 CA CA2554195A patent/CA2554195C/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002525382A (ja) * | 1998-09-25 | 2002-08-13 | ザ チルドレンズ メディカル センター コーポレイション | プロテインキナーゼの活性を選択的に調節するショートペプチド |
Non-Patent Citations (11)
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7887805B2 (en) | 2007-03-01 | 2011-02-15 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
US8414896B2 (en) | 2007-03-01 | 2013-04-09 | Symphogen A/S | Recombinant anti-epidermal growth factor receptor antibody compositions |
US9102715B2 (en) | 2007-09-18 | 2015-08-11 | Green Peptide Co., Ltd. | CTL inducer composition |
US9642900B2 (en) | 2007-09-18 | 2017-05-09 | Green Peptide Co., Ltd. | CTL inducer composition |
EP2196209A4 (en) * | 2007-09-18 | 2010-11-24 | Greenpeptide Co Ltd | INDUCTIVE COMPOSITION OF CYTOTOXIC T LYMPHOCYTES |
JP5568309B2 (ja) * | 2007-09-18 | 2014-08-06 | 株式会社グリーンペプタイド | Ctl誘導剤組成物 |
EP2801367A1 (en) | 2007-09-18 | 2014-11-12 | Green Peptide Co., Ltd. | CTL inducer composition |
EP2196209A1 (en) * | 2007-09-18 | 2010-06-16 | Green Peptide Co., Ltd. | Ctl inducer composition |
EP3494981A1 (en) | 2007-09-18 | 2019-06-12 | BrightPath Biotherapeutics Co., Ltd. | Ctl inducer composition |
EP3156061A1 (en) | 2007-09-18 | 2017-04-19 | Green Peptide Co., Ltd. | Ctl inducer composition |
US8663640B2 (en) | 2008-08-29 | 2014-03-04 | Symphogen A/S | Methods using recombinant anti-epidermal growth factor receptor antibody compositions |
JP2017029135A (ja) * | 2008-10-01 | 2017-02-09 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 神経細胞性脳腫瘍など数種の腫瘍に対する新規免疫療法 |
WO2012005161A1 (ja) | 2010-07-07 | 2012-01-12 | 株式会社グリーンペプタイド | がんペプチドワクチン |
US10137183B2 (en) | 2013-10-21 | 2018-11-27 | Taiho Pharmaceutical Co., Ltd. | Peptide compositions having 4 linked CTL epitopes and uses thereof |
WO2020004622A1 (ja) | 2018-06-29 | 2020-01-02 | 大鵬薬品工業株式会社 | 抗腫瘍剤及びその評価方法 |
CN113518574A (zh) * | 2019-03-05 | 2021-10-19 | 奥林巴斯株式会社 | 内窥镜装置和图像处理方法 |
WO2021132550A1 (ja) | 2019-12-26 | 2021-07-01 | 大鵬薬品工業株式会社 | 術後補助療法剤 |
Also Published As
Publication number | Publication date |
---|---|
US7655751B2 (en) | 2010-02-02 |
JPWO2005071075A1 (ja) | 2007-09-06 |
JP4579836B2 (ja) | 2010-11-10 |
CA2554195A1 (en) | 2005-08-04 |
EP1712620A4 (en) | 2008-05-28 |
US20080119399A1 (en) | 2008-05-22 |
EP1712620A1 (en) | 2006-10-18 |
CA2554195C (en) | 2011-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4579836B2 (ja) | 上皮細胞増殖因子受容体(egfr)由来ペプチド | |
JP7437939B2 (ja) | 集団に基づいた免疫原性ペプチドの同定のプラットフォーム | |
CN112979783B (zh) | 获得肿瘤特异性t细胞受体的方法 | |
Norell et al. | Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial | |
EP1923463B1 (en) | Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen | |
JP2021521776A (ja) | Mage−b2特異性を有するt細胞受容体およびその使用 | |
US20070031431A1 (en) | Tumor antigen | |
MX2014011136A (es) | Peptidos cancerigenos universales derivados de telomerasa. | |
Rosenbaum et al. | The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients | |
WO2014098012A1 (ja) | ヘルパーt細胞の活性化方法 | |
AU2013357239B2 (en) | Novel MHC-independent tumor-associated antigens | |
JP2021502110A (ja) | がん特異的抗原に対するtリンパ球のスクリーニング | |
Hos et al. | Cancer-specific T helper shared and neo-epitopes uncovered by expression of the MHC class II master regulator CIITA | |
EA037271B1 (ru) | Мультипептидный т-специфичный иммунотерапевтический препарат для лечения метастазов рака в головном мозге | |
KR20110134482A (ko) | Sox2 유래의 hla-a24결합성 암 항원 펩티드 | |
US20180155403A1 (en) | Histone anti-cancer vaccines | |
Shomura et al. | Identification of epidermal growth factor receptor-derived peptides recognised by both cellular and humoral immune responses in HLA-A24+ non-small cell lung cancer patients | |
Shomura et al. | Identification of epidermal growth factor receptor-derived peptides immunogenic for HLA-A2+ cancer patients | |
CN114853880A (zh) | Wt1抗原特异性t细胞受体及其抗肿瘤用途 | |
Ishihara et al. | HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients | |
JP4443202B2 (ja) | Cd4陽性t細胞に認識されるペプチド | |
Hendrickson et al. | Identification of a 17β-hydroxysteroid dehydrogenase type 12 pseudogene as the source of a highly restricted BALB/c Meth A tumor rejection peptide | |
AU2022358605A1 (en) | A dna vaccine for use in the therapeutic and/or prophylactic treatment of tumor diseases | |
EA045699B1 (ru) | Персонализированная платформа для идентификации иммуногенного пептида | |
Emens et al. | Enhancement of an Allogeneic GM-CSF-Secreting Breast Cancer Vaccine by Immunomodulatory Doses of Cyclophosphamide and Doxorubicin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517285 Country of ref document: JP Ref document number: 2554195 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005704007 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2005704007 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10586499 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 10586499 Country of ref document: US |